BMS Revise Yearly Earnings Estimate Up On Strong Q211 Results

BMI View: Bristol-Myers Squibb (BMS) has less exposure to the markets beyond the US, so its success relies more heavily on its pipeline and current blockbuster drugs to maintain investor value. In an effort to boost revenues in Q211, the company increased drug prices in the US, but will nevertheless need its most promising pipeline drugs Yervoy (ipilimumab) and Eliquis (apixaban) to sell well to offset the loss of revenues from Plavix (clopidogrel) in May 2012 and its lack of emerging market exposure. We believe BMS's share price will perform in line with its peers in the pharmaceutical industry for

To read the full article, please choose one of the following options: